Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin

Journal of Psychopharmacology

Volumn 18, Issue 3, 2004, Pages 432-434

  Webber, Michael A ^a   Mahmud, Waqar ^a   Lightfoot, Jeffery D ^a   Shekhar, Anantha ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compartment syndrome; Hyperlipidemia; Rhabdomyolysis; Risperidone; Schizophrenia; Simvastatin

Indexed keywords

CLONAZEPAM; CYTOCHROME P450; QUETIAPINE; RISPERIDONE; SIMVASTATIN;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; COMPARTMENT SYNDROME; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; ERYTHEMA; FEVER; HUMAN; HYPERLIPIDEMIA; LEG INJURY; LEG PAIN; LEG SWELLING; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SCHIZOPHRENIA;

ACUTE DISEASE; ADULT; ANTILIPEMIC AGENTS; ANTIPSYCHOTIC AGENTS; COMPARTMENT SYNDROMES; DRUG INTERACTIONS; HUMANS; HYPERLIPIDEMIAS; MALE; RHABDOMYOLYSIS; RISPERIDONE; SCHIZOPHRENIA; SIMVASTATIN;

EID: 6044255039     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110401800316     Document Type: Article

References (16)

1. Bogaerts Y, Lameire N, Ringoir S (1982) The compartmental syndrome: a serious complication of acute rhabdomyolysis. Clin Nephrol 77: 206-211
2. Domon S E, Cargile C S (2002) Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 41: 495-496
3. Fang J, Bourin M, Baker G B (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn- Schmiedeberg's Arch Pharmacol 359: 147-151
4. Giner V, Munoz R, Redon J (2002) Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 257: 177-178
5. Hargreaves S (2003) NICE guidelines address social aspect of schizophrenia. BMJ 326: 679
6. Hiratsuka M, Mizugaki M (2001) Genetic polymorphisms in drug-metabolizing enzymes and drug targets. Mol Genet Metab 73: 298-305
7. Jaanson P, Marandi T, Kiivet R, Vasar V, Vaan S, Svensson J, Dahl M (2002) Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP 2D6 genotype. Psychopharmacology 162: 67-73
8. Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka K (2000) Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 10: 145-147
9. McIntyre R S, McCann S M, Kennedy S H (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46: 273-281
10. NICE Guidelines (2003) Royal College of Psychiatrists. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care http://www.rcpsych.ac.uk
11. Omar M A, Wilson J P, Cox T S (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35: 1096-1107
12. Prior T I, Baker G B (2003) Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28: 99-112
13. Rubio-Gozalbo M E, van Waardenburg D A, Forget P P, Spaapen L J M, Verrips A, Vroomen P C A J (2001) Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy. J Inherit Metab Dis 24: 605-606
14. Schneider J M, Roger D J, Uhl R L (1996) Bilateral forearm compartment syndromes resulting from neuroleptic malignant syndrome. J Hand Surg (Am) 21A: 287-289
15. Tiwari A, Haq A I, Myint F, Hamilton G (2002) Acute compartment syndromes. Br J Surg 89: 397-412
16. Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41: 343-370